¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"early neonatal mortality rate"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • cause-specific rate
    ¿øÀκ°ºñÀ²
  • cerebral metabolic rate
    ³ú´ë»çÀ²
  • child death rate
    ¼Ò¾Æ»ç¸Á·ü
  • defect rate
    °áÇÔ·ü
  • death rate
    »ç¸Á·ü
  • diffusion rate
    È®»êÀ²
  • disability rate
    Àå¾ÖÀ²
  • disappearance rate
    ¼Ò½Ç·ü
  • divorce rate
    ÀÌÈ¥À²
  • dose rate
    1. ¼±·®·ü 2. Åõ¿©·®
  • dose rate effect
    ¼±·®·üÈ¿°ú
  • dose rate meter
    ¼±·®·ü°è, ¼±·®·üÃøÁ¤±â
  • exponential growth rate
    Áö¼öÁõ½Ä·ü, Áö¼ö¼ºÀå·ü
  • exposure rate
    ³ëÃâ·ü, ÇÇÆø·ü
  • exposure rate constant
    ÇÇÆø·ü»ó¼ö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • corrected life birth rate
    Á¤Á¤Ãâ»ý·ü
  • crude birth rate
    Á¶Ãâ»ý·ü
  • crude death rate
    º¸Åë»ç¸Á·ü, Á¶»ç¸Á·ü
  • crude fertility rate
    Á¶»ý½Ä·ü, Á¶¼öÅÂÀ²
  • crude natural increase rate
    Á¶ÀÚ¿¬Áõ°¡À², º¸ÅëÀÚ¿¬Áõ°¡À²
  • crude survival rate
    Á¶»ýÁ¸À²
  • cumulative death rate
    ´©Àû»ç¸Á·ü
  • cumulative incidence rate
    ´©Àû¹ß»ý·ü
  • cumulative survival rate
    ´©Àû»ýÁ¸À²
  • cure rate
    Ä¡À¯À²
  • exposure rate constant
    ÇÇÆø·ü»ó¼ö
  • growth rate constant
    Áõ½Ä·ü»ó¼ö
  • kerma rate constant
    Ä¿¸¶À²»ó¼ö
  • rate constant
    ¼Óµµ»ó¼ö
  • death rate
    »ç¸Á·ü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • alloimmune neonatal thrombocytopenia=ANN
    µ¿Á¾¸é¿ª¼º½Å»ý¾ÆÇ÷¼ÒÆÇ°¨¼ÒÁõ
  • eruptive neonatal angiomatosis
    ¹ßÁø¼º ½Å»ý¾Æ Ç÷°üÁ¾Áõ
  • isoimmune neonatal neutropenia
    ½Å»ý¾Æµ¿Á¾¸é¿ª¼º È£Áß±¸°¨¼Ò(Áõ).
  • neonatal
  • neonatal =neonate
    ½Å»ý¾Æ(ãæßæä®)ÀÇ, ½Å »ý¾Æ.
  • neonatal adnexal polyp
    ½Å»ý¾Æ ºÎ¼Ó±â ¿ëÁ¾
  • neonatal alloimmune thrombocytopenia=NAIT
    ½Å»ý¾Æµ¿Á¾¸é¿ªÇ÷¼ÒÆÇ °áÇÌÁõ
  • neonatal anemia
    ½Å»ý¾ÆºóÇ÷(~Þ¸úì).
  • neonatal anesthesia
    ½Å»ý¾Æ¸¶Ãë
  • neonatal apoplexy
    ½Å»ý¾Æ(³ú)Á¹Áõ(~Òàðïñø).
  • neonatal asphyxia
    ½Å»ý¾Æ°¡»ç(~Ê£ÞÝ), ½Å»ý¾ÆÁú½Ä.
  • neonatal atelectasis
    ½Å»ý¾Æ¹«±âÆó(~ÙíѨøË).
  • neonatal blennorrh[o]ea
    ½Å»ý¾Æ ¾È³ó·ç
  • neonatal calf diarrhea coronavirus
    ½Å»ý¼Ò ¼³»ç Äڷγª¹ÙÀÌ·¯½º
  • neonatal cold injury
    ½Å»ý¾Æ ÇÑ·© ¼Õ»ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
ASMR age-standardized mortality ratio
CPNM corrected perinatal mortality
MM macromolecule; Maelzels metronome; major medical [insurance]; malignant melanoma; manubrium to malle...
M&M morbidity and mortality
MMWR Morbidity and Mortality Weekly Report
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
MMR Maternal mortality ratio
MR mortality ratio
MOR mortality odds ratio
OM Operative mortality
PRISM Paediatric Risk of Mortality
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • overall rate
    ÃÑüÀû ºñÀ²
  • peak flow rate
    ÃÖ´ë À¯¼Ó, ÃÖ°í À¯¼Ó
  • prevalance rate
    À¯º´À²
  • prevalence rate
    À¯º´·ü
  • processing rate
    ½Ã¼ú È¿À²
  • rate dependent bundle branch block
    ½É¹Ú ¼ö ÀÇÁ¸¼º °¢ Â÷´Ü
  • rate of ablation
    Á¦°ÅÀ²
  • rate of polymerization
    ÁßÇÕ·ü
  • rate of teeth decayed
    ¿ì½Ä·ü
  • rate-limiting enzyme
    ¼Óµµ Á¶Àý È¿¼Ò
  • repetition rate
    ¹Ýº¹À²
  • respiratory rate
    È£ÈíÀ²
    ¼ºÀÎÀÇ °æ¿ì È£ÈíÀº 1ºÐ¿¡ 16~18ȸ ¾î¸°ÀÌ´Â 24~28ȸ Á¤µµ°¡ Á¤»óÀÌ´Ù.
  • salivary flow rate
    Ÿ¾× ºÐºñÀ²
  • sedimentation rate
    ħ°­À², ħ°­ ¼Óµµ
    µ¿ÀǾî=erythrocyte sedimentation rate.
  • stillbirth rate
    »ç»êÀ²
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
neonatal tooth A tooth erupting up to 30 days after birth.
(05 Mar 2000)
intensive care, neonatal Continuous care and monitoring of newborn infants with life-threatening conditions, in any setting.
(12 Dec 1998)
intensive care units, neonatal Hospital units providing continuing surveillance and care to acutely ill newborn infants.
(12 Dec 1998)
isoimmune neonatal thrombocytopenia Immune thrombocytopenia resulting from maternal-foetal platelet incompatibility.
(05 Mar 2000)
jaundice, neonatal The jaundice sometimes seen in newborn infants. It is also called icterus neonatorum.
(12 Dec 1998)
abortion rate The number of abortions per 1000 terminated pregnancies during a given period of time.
(05 Mar 2000)
age-specific rate A rate for a specified age group, in which the numerator and denominator refer to the same age group.
(05 Mar 2000)
attack rate A cumulative incidence rate used for particular groups observed for limited periods under special circumstances, such as during an epidemic.
(05 Mar 2000)
average flow rate <physiology> The flow rate determined by dividing the total volume passed in a time period divided by the time period, usually quoted in mls per minute.
(05 Mar 2000)
backup rate A utility charge for providing occasional electricity service to replace on-site generation.
(05 Dec 1998)
basal metabolic rate <biochemistry, biology> The metabolic rate as measured under basal conditions: 12 hours after eating, after a restful sleep, no exercise or activity preceding test, elimination of emotional excitement and occurring in a comfortable temperature.
Acronym: BMR
(15 Nov 1997)
baseline foetal heart rate <paediatrics> The average heart rate for a particular foetus during the diastolic phase of uterine contractions.
(05 Mar 2000)
baseline variability of foetal heart rate The beat-to-beat changes in foetal heart rate as recorded on a graph.
(05 Mar 2000)
basic reproductive rate, ratio <epidemiology> See Reproductive Ratio.
(05 Dec 1998)
birth rate The birth rate is usually given as the number of live births divided by the average population (or the population at midyear). This is termed the crude birth rate. In 1995, for example, the crude birth rate per 1,000 population was 14 in the United States, 16.9 in Australia, etc.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á